Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in Ordinary Share American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The filing details a specific transaction arising from the reinvestment of a dividend paid to Ordinary Share ADR holders on July 6, 2006, through the US Global BuyDirect Plan administered by The Bank of New York.
- Person: Mrs. P. Phelan
- Transaction: Acquired a beneficial interest in 0.2185 Ordinary Share ADRs.
- Price: $56.9329 per ADR.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share acquisition described above in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the dividend reinvestment plan details for the July 6, 2006 payment date.
- Confirm the identity and role of Mrs. P. Phelan within the company's governance structure.
- Note that this filing does not contain financial performance data for the period.